Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» EQRx
EQRx
EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing
BioPharma Dive
Wed, 08/2/23 - 10:23 am
EQRx
drug pricing
Revolution Medicines
Orbital shows 2023’s venture funding scene is far from stratospheric
EP Vantage
Fri, 05/19/23 - 10:06 am
RNA
funding
venture capital
Altos Labs
CureVac
EQRx
Hasten Biopharmaceutic
Orbital Therapeutics
Sana Biotechnology
Suzhou Abogen Biosciences
TORL BioTherapeutics
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
Endpoints
Mon, 06/6/22 - 10:31 am
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
Biotech's top 10 money raisers of 2021
Fierce Biotech
Mon, 04/18/22 - 11:02 am
biotech
funding
Abogen
Elevate Bio
EQRx
Neumora
Laronde Therapeutics
Adagio Therapeutics
Sotio
Altos Labs
Sonoma Biotherapeutics
Insilico
EQRx adds armor to its discount checkpoint inhibitor submission, nailing survival mark in key study
Endpoints
Tue, 01/18/22 - 11:55 pm
EQRx
CStone Pharmaceuticals
sugemalimab
EQRX aims for biopharma SPAC record
EP Vantage
Wed, 08/11/21 - 12:09 pm
SPAC
EQRx
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs: a look ahead at ASCO
BioPharma Dive
Thu, 05/20/21 - 11:18 pm
ASCO 2021
Allogene
CAR-T
Bristol Myers Squibb
EQRx
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EP Vantage
Fri, 07/24/20 - 09:27 am
Pfizer
AstraZeneca
EQRx
drug pricing
Ibrance
Tagrisso
A Pharma Startup Launches With $200 Million In Funding And A Strategy To Make Drugs Faster, Cheaper
Forbes
Sun, 01/12/20 - 11:35 pm
drug pricing
EQRx
Alex Borisy